tiprankstipranks
Trending News
More News >

Twist Bioscience backs FY25 revenue view $372M-$379M, consensus $375.33M

Raises FY25 adjusted EBITDA loss view to $48M-$53M from $55M-$60M. The company said, “Gross margin is projected to be approximately 49.5% for fiscal 2025 with quarterly sequential improvements, compared to previous guidance of 49.0% and 4QFY25 gross margin is projected to be over 50.0%.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue